Prophylaxis for Pneumocystis jirovecii pneumonia (PJP) is recommended for patients undergoing hematopoietic stem cell transplantation (HSCT) or intensive chemotherapy. Trimethoprim-sulfamethoxazole and inhaled pentamidine are used frequently, but are limited, by their tolerability and therefore compliance. Intravenous (IV) pentamidine is a potential alternative agent. Here we conducted the first prospective study of the safety and efficacy of IV pentamidine for PJP prophylaxis in adult patients undergoing HSCT or intensive chemotherapy (clinicaltrials.gov NCT02669706). Fifty patients requiring PJP prophylaxis were enrolled and received monthly IV pentamidine at 4 mg/kg (maximum 300 mg) while undergoing intensive chemotherapy or HSCT. Patients were followed for the occurrence of PJP pneumonia and for adverse events. Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM Version 1.4) survey. Seventeen (34%) patients experienced a grade 1 or 2 adverse event. There were no grade 3/4 events. The TSQM questionnaire indicated that the majority of patients were satisfied with the administration of IV pentamidine (n = 43, 86%, p = 0.01). There were no cases of PJP during the 24 month follow-up period. Our study illustrates the safety, feasibility, and high degree of patient satisfaction when using IV pentamidine for PJP prophylaxis.
Introduction
Patients undergoing hematopoietic stem cell transplantation (HSCT) or intensive chemotherapy for hematologic malignancies are at an increased risk for opportunistic bacterial, viral, and fungal infections. Pneumocystis jirovecii pneumonia (PJP) affects 5-15% of patients within a year of HSCT and is fatal in two-thirds of cases [1, 2] . Guidelines published by the Centers for Disease Control and Prevention (CDC), the American Society for Blood and Marrow Transplant, and the European Conference on Infections in Leukemia recommend routine PJP prophylaxis in patients who are undergoing HSCT, diagnosed with acute lymphocytic leukemia (ALL), receiving lymphodepleting chemotherapy such as alemtuzumab or fludarabine, or receiving corticosteroid equivalents of prednisone ≥20 mg per day for 4 weeks [1, 3, 4] .
On the basis of the low breakthrough rates of PJP observed in clinical trials, primary prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) remains the gold standard among HSCT recipients [1] . However, its use is limited by myelosuppression and the potential for delaying white cell engraftment after HSCT [5, 6] . Although not extensively studied, inhaled pentamidine, dapsone, and atovaquone have been used for patients who cannot tolerate TMP-SMX. These agents may also be difficult to administer because of toxicities and logistic challenges. In addition, breakthrough PJP infection may occur at a higher rate as compared to TMP-SMX. An alternative drug that is feasible, safe, and effective is needed in patients undergoing intensive chemotherapy or HSCT.
Intravenous (IV) pentamidine is FDA-approved for the treatment of PJP, is not myelosuppressive, and exhibits few of the adverse effects of its inhaled equivalent [7] [8] [9] [10] . Given these potential advantages, we conducted a prospective study evaluating the efficacy, safety, and tolerability of IV pentamidine when given for PJP prophylaxis in patients undergoing intensive chemotherapy or HSCT.
Materials and methods

Study design and eligibility
The study was approved by the University of Illinois Institutional Review Board. Patients were required to sign an informed consent before receiving their first dose of IV pentamidine. Adult patients who were at least 18 years of age and who met institutional guidelines for administration of PJP prophylaxis were eligible. This included patients undergoing autologous or allogeneic stem cell transplant who were within 180 days of HSCT, recipients of allogeneic transplants who had chronic graft vs. host disease and were on immunosuppression, and patients who were undergoing intensive chemotherapy where routine PJP prophylaxis was recommended based on institutional guidelines. Of note, previous administration of inhaled or IV pentamidine was not an exclusion criterion for this study. Patients were excluded if they were pregnant, or had any documented allergy or hypersensitivity to pentamidine. In addition, as IV pentamidine is an irritant with vesicant like properties, patients were excluded if they did not have central venous access. All patients who received at least one dose of IV pentamidine were included in the final analysis. The primary end point was to assess the safety of IV pentamidine for PJP prophylaxis. A secondary end point was to assess patient satisfaction with the administration of IV pentamidine. Although it was not an outlined end point, occurrence of PJP was also monitored during the study period.
Treatment regimen
All participants received IV pentamidine at 4 mg/kg of actual body weight once a month with a maximum of 300 mg per dose. Pentamidine was infused over 2 h through a central venous catheter. To prevent nausea and vomiting, IV ondansetron 8 mg was administered 30 min to 1 h prior to IV pentamidine. In patients undergoing HSCT, IV pentamidine was administered anytime from the end of conditioning chemotherapy to discharge from the hospital.
Toxicity and engraftment measurement
Adverse events were recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4. Toxicities were independently assessed by two clinical pharmacists. Following this, all biochemical toxicities were arbitrated by an independent physician. Prior studies evaluating IV pentamidine for the treatment of PJP have reported both acute infusion-related adverse events as well as delayed, chronic reactions such as hyperglycemia and QT prolongation. Since delayed reactions are known to happen with longer courses of pentamidine for the treatment of PJP (i.e., greater than 14 days), we implemented a shorter surveillance period for monitoring of adverse events in our study. Thus, patients were monitored for adverse events during the drug infusion, for the first 8 h after the infusion, and for 1 week after receiving IV pentamidine. If any laboratory abnormalities were observed after the administration of IV pentamidine, monitoring was extended beyond a week until they normalized. To monitor for infusion-related reactions, vital signs were measured on all patients at baseline, 1 h after the end of the infusion, and periodically thereafter based on clinical judgment. A basic metabolic panel, liver function tests, and a complete blood count with differential were drawn at least twice in the week following infusion and more frequently if clinically indicated. In patients who experienced a decrease in systolic blood pressure to less than 90 mm Hg, pentamidine was held and patients received an IV fluid bolus of 500-1000 mls of 0.9% normal saline. Pentamidine could be subsequently restarted once blood pressure recovered. Since QT prolongation is associated with prolonged courses of IV pentamidine, EKG measurements were not routinely performed in our study [11] . For patients undergoing stem cell transplantation, neutrophil engraftment was defined as an absolute neutrophil count >0.5 × 10 9 /l for 3 consecutive days and platelet engraftment was defined as >20 × 10 9 /l without transfusion for 7 days. Patients were monitored on a weekly basis for PJP pneumonia for 12 months.
Patient satisfaction
Patient satisfaction was assessed by conducting the Treatment Satisfaction Questionnaire for Medication (TSQM Version 1.4) survey [12] [13] [14] , which was administered verbally within 24 h of IV pentamidine completion. This is a widely used tool to measure a patient's treatment satisfaction with medications, and consists of multiple-choice questions, each with five response options ( Table 1) . Patient-reported adverse events are also reported using this tool.
Statistical analysis
Clinical and laboratory data are reported as the median values with range. Continuous variables were compared by t-test, when appropriate. The mean scores in the TSQM questionnaire were compared using ANOVA. TSQM questionnaire results were compared using Χ 2 -test. GraphPad Prism (GraphPad, La Jolla, CA) was utilized for all analyses. AA African Americans, AML/MDS acute myeloid leukemia/myelodysplastic syndrome, ALL acute lymphoblastic lymphoma, MM multiple myeloma, NHL/HL non-Hodgkin's lymphoma/Hodgkin's lymphoma, SCT stem cell transplantation, BEAM BCNU, etoposide, ara-C, melphalan, MA myeloablative, NMA/RIC nonmyeloablative/ reduced-intensity conditioning, GVHD graft vs. host disease, aGVHD acute GVHD, cGVHD chronic GVHD, ANC absolute neutrophil count, ALC absolute lymphocyte count
Results
Patient characteristics
Fifty consecutive patients met eligibility criteria and were included in the final analysis. Baseline characteristics are summarized in Table 2 . Thirty-two (64%) patients were male, and the median age was 55 years (range: 19-72). Thirteen (26%) patients were African-American and 17 (34%) were white. Diagnoses included acute myeloid leukemia (n = 16, 32%), multiple myeloma (n = 12, 24%), ALL (n = 5, 10%), Hodgkin's and non-Hodgkin's lymphoma (n = 8, 16%), chronic myeloid leukemia (n = 3, 6%), and other hematologic disorders such as aplastic anemia, sickle cell disease, and AL amyloidosis (n = 6, 12%). Twenty-four patients (48%) were undergoing intensive chemotherapy, while 26 (52%) were undergoing HSCT. Patients undergoing HSCT received IV pentamidine anytime after conditioning chemotherapy until the day of hospital discharge. Chemotherapy regimens are summarized in Table 3 . Of patients undergoing stem cell transplant, 16 (62%) received autologous HSCT, while 10 (38%) received allogeneic HSCT. The conditioning regimen for autologous HSCT was high-dose melphalan in 13 (81%) patients, while 3 (19%) received carmustine, etoposide, cytarabine, and melphalan. Of patients undergoing allogeneic HSCT, three (30%) patients received myeloablative conditioning, while the remaining seven (70%) patients received either a nonmyeloablative or reduced-intensity conditioning regimen. At the time of first IV pentamidine administration, 58% of patients were neutropenic (absolute neutrophil count <0.5 thous/µl) and 86% of patients were lymphopenic (absolute lymphocyte count <1 thous/µl). The median number of IV pentamidine doses administered was 2 (range: 1-9). All patients received at least one dose of IV pentamidine (range: 1-9). Five (10%) patients had received prior inhaled pentamidine, while nine (18%) patients had received prior IV pentamidine.
Efficacy and safety outcomes
Patients were followed for toxicity for 1 week after receiving IV pentamidine. There were no NCI-CTCAE grade 3/4 events. Seventeen (34%) patients experienced a grade 1 or 2 adverse event. The most common adverse events were nausea (n = 4) and hypotension (n = 6). Hypotension occurred either during or at the end of the infusion, was transient, and asymptomatic. Other adverse events were rash (n = 1), oral numbness (n = 2), and nasal congestion (n = 2). Grade 1/2 acute kidney injury developed in two patients (4%). In both patients, serum creatinine increased within 3 days, peaked within 7 days, and normalized within 10 days. Two treatment-related interruptions of drug infusion occurred. The first interruption was due to infusionrelated perioral and facial numbness, which resolved as soon as the drug was stopped and the second was due to nausea, which resolved after intravenous ondansetron. IV infusion was resumed successfully in both cases. Both patients received subsequent monthly IV pentamidine doses without complications. Engraftment was not adversely affected in patients undergoing HSCT. The median time to neutrophil and platelet engraftment was 12 (range: 11-15) and 14 (range: 10-16) days in autologous SCT recipients and 13 (range: 13-31) and 14 (range: 14-31) days in allogeneic SCT recipients. There were no cases of PJP documented during our study. After a median follow-up of 566 days, five (10%) patients died due to reasons related to the primary malignancy or complications of chemotherapy or HSCT. 
Patient satisfaction outcomes
Results from the TSQM questionnaire ( Fig. 1) indicate that the majority of patients found that IV pentamidine was "not at all bothersome" (n = 33, 69%), "did not interfere with physical health and ability to function" (n = 37, 77%), and was "extremely easy to receive" (n = 29, 60%). The most common patient-reported adverse events in the TSQM questionnaire were nausea (n = 6), nasal congestion (n = 2), and mouth numbness (n = 2). However, they had "minimal" or "no effect at all" on patient satisfaction with the drug. Overall patients were satisfied with the administration of IV pentamidine (n = 43, 86%, p < 0.01).
Discussion
Here we report the first prospective study of the tolerability and efficacy of IV pentamidine PJP prophylaxis in adult patients undergoing stem cell transplantation or intensive chemotherapy. We show minimal toxicity and a high degree of patient satisfaction with administration of this regimen. Although TMP-SMX is the drug of choice for primary PJP prophylaxis, it is often poorly tolerated in patients with hematologic diseases [1, 3, 4] . In particular, myelosuppression is common and becomes problematic during the HSCT engraftment period and when longer courses of prophylaxis are required [5, 6] . These issues lead to high rates (31-56%) of early cessation of the drug in HSCT recipients [1] . Dapsone, inhaled pentamidine, and atovaquone have also been studied in this patient population but each is characterized by a unique toxicity or administration profile. In particular, use of inhaled pentamidine is limited by administration challenges [1, 4, 15, 16] including the need to adhere to US National Institute of Occupational Health and Safety safe handling procedures [10] . Also, poor compliance due to acute bronchospasm, cough, sore throat, and difficulty in administration in patients with mucositis leads to a 10% discontinuation rate [8, 9, 17, 18] . Most importantly, dapsone, inhaled pentamidine, and atovaquone have shown to be less effective than TMP-SMX for firstline PJP prophylaxis [18, 19] .
IV pentamidine overcomes many of these disadvantages but has not been well studied for PJP prophylaxis among adult patients with only a single retrospective study in 113 adults showed that IV pentamidine was effective and well tolerated [20] . Retrospective data in the pediatric population support a low rate of breakthrough PJP infection with minimal toxicities [20] [21] [22] [23] [24] [25] [26] . Kim et al. [26] performed a retrospective review of pediatric patients receiving 4 mg/kg of IV pentamidine monthly, and showed a breakthrough PJP rate of 1.3% with no observed toxicities. DeMasi et al. [25] found no episodes of breakthrough PJP in children who underwent HSCT and received IV pentamidine as first-line primary PJP prophylaxis. Of 137 patients, 10 experienced nausea/vomiting, 2 had anaphylaxis, and 17 hypotension. Additional toxicities were mild and limited to nausea and vomiting.
Our data confirmed the favorable safety profile of IV pentamidine with no breakthrough infections. Consistent with prior retrospective studies evaluating IV pentamidine for prophylaxis, we found that delayed or chronic toxicities such as hyperglycemia, pancreatitis, and arrhythmia were not observed in our study. Thus, monitoring for these reactions is unnecessary when giving monthly IV pentamidine. Common toxicities observed in our study were grade ≤2 nausea and hypotension. All four cases of hypotension were asymptomatic and reversible without intervention. On the basis of these findings, we would recommend close monitoring for hypotension and nausea after the infusion. Infrequent grade 3 and 4 toxicities such as acute pancreatitis or anaphylaxis reported in retrospective pediatric studies were not seen in our patients. In HSCT patients, IV pentamidine did not delay engraftment. Furthermore, in patients undergoing lymphodepleting chemotherapy, TMP-SMX has typically been administered and data on the use of other agents is lacking. Our study shows safety and feasibility of IV pentamidine in a significant number of these patients who are undergoing lymphodepleting regimens for which PJP prophylaxis is recommended. Patients with non-hematologic indications for PJP prophylaxis, such as recipients of solid organ transplants, may also benefit from this method of prophylaxis. Of note, IV pentamidine does not share the same spectrum of activity as TMP-SMX. Therefore, microorganisms that are adequately covered by TMP-SMX including Toxoplasma gondii, Nocardia Asteroides, and Listeria monocytogenes are not covered with IV pentamidine. If prophylaxis against these is necessary, an alternative or an additional agent would be warranted.
Although comparative studies demonstrating efficacy are required to recommend this as the standard method of prophylaxis in patients undergoing intensive chemotherapy or HSCT, IV pentamidine overcomes many of the challenges faced when administering inhaled pentamidine or TMP/SMX. Given that the reduced toxicity of IV pentamidine should be balanced with the need for antiemetic and maintenance of a central venous catheter, a cost utilization comparison with other methods of PJP prophylaxis would also be beneficial. We conclude that patients who are intolerant to standard PJP prophylactic agents may derive benefit from the tolerability, feasibility, and patient satisfaction profile of IV pentamidine.
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